Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sirolimus

sirolimus

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sirolimus

96 trials tracked of sirolimus: 24 in phase 3 or 4 and 6 with published results. The most-cited published study has 1121 citations.

96Trials tracked
24Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 11 Phase 3 13 Phase 2 62 Phase 1 3 Other / NA 7
  1. Phase 3 Efficacy and Safety of Sirolimus in LAM Completed · 1,121 cited
  2. Phase 3 Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission Completed · 224 cited
  3. Phase 3 Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy Completed · 149 cited
  4. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 112 cited
  5. Phase 3 TBI Dose De-escalation for Fanconi Anemia Completed · 111 cited
  6. Phase 4 Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation Completed · 10 cited
Show 44 more trials
  1. Phase 4 Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients Completed
  2. Phase 4 Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic Completed
  3. Phase 4 Improved Induction and Maintenance Immunosuppression in Kidney Transplantation Completed
  4. Phase 4 Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients Completed
  5. Phase 4 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed
  6. Phase 4 Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant Completed
  7. Phase 4 Comparison of Sirolimus and Azathioprine in Lung Transplantation Completed
  8. Phase 4 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed
  9. Phase 4 Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients Completed
  10. Phase 4 Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients Completed
  11. Phase 3 Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans Completed
  12. Phase 3 Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Completed
  13. Phase 3 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Completed
  14. Phase 3 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Completed
  15. Phase 3 Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Completed
  16. Phase 3 Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients Completed
  17. Phase 3 Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Completed
  18. Phase 3 Study Evaluating Sirolimus in Kidney Transplant Recipients Completed
  19. Phase 2 Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection Completed
  20. Phase 2 In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Completed
  21. Phase 2 Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects Completed
  22. Phase 2 Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Completed
  23. Phase 2 Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes Completed
  24. Phase 2 Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Completed
  25. Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
  26. Phase 2 Islet Transplantation for Type 1 Diabetes Completed
  27. Phase 2 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Completed
  28. Phase 2 Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Completed
  29. Phase 2 Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD Completed
  30. Phase 2 Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas Completed
  31. Phase 2 Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Completed
  32. Phase 2 Rapalogues for Autism Phenotype in TSC: A Feasibility Study Completed
  33. Phase 2 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD Completed
  34. Phase 2 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Completed
  35. Phase 2 Sirolimus Injections for Autoimmune Scleritis Completed
  36. Phase 2 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Completed
  37. Phase 2 Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Completed
  38. Phase 2 Sirolimus and Familial Adenomatous Polyposis (FAP) Completed
  39. Phase 2 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Completed
  40. Phase 2 A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation Completed
  41. Phase 2 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed
  42. Phase 2 Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults Completed
  43. Phase 2 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Completed
  44. Phase 2 Sirolimus to Treat Diabetic Macular Edema Completed

Showing the 50 most-cited and recently-updated of 96 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Drug-coated devices associated with HR 1.86 for wound healing in chronic limb-threatening ischemia
Cardiology RCT
Drug-coated devices associated with HR 1.86 for wound healing in chronic limb-threatening ischemia Drug coated devices may help wound healing for limb ischemia
This prospective single-center service evaluation of 341 patients with chronic limb-threatening ischemia found that drug-coated device use w…
New data suggests that using drug coated devices during surgery can lead to more frequent wound healing for people with severe leg blood flo…
medRxiv Jul 17, 2026
Sirolimus and paclitaxel-coated balloons show similar outcomes for coronary in-stent restenosis
Cardiology Meta-analysis
Sirolimus and paclitaxel-coated balloons show similar outcomes for coronary in-stent restenosis Sirolimus and paclitaxel balloons show similar results for heart disease
This GRADE-assessed systematic review and meta-analysis of 3,633 participants with coronary artery disease found no notable variations betwe…
Two drug-coated balloons for coronary artery disease work about equally well, a new analysis finds.
Jun 1, 2026
Systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in coronary artery disease
Cardiology Meta-analysis
Systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in coronary artery disease Meta-analysis links drug balloons to higher heart risks
This systematic review and meta-analysis evaluated drug-coated balloons (DCB) versus drug-eluting stents (DES) in 8,123 patients with corona…
A review of 8,123 patients found drug-coated balloons for heart arteries may raise risks of repeat procedures and cardiac death compared to …
Frontiers May 18, 2026
Review of preclinical interventions for heat stroke pathophysiology and gaps
Drug Pipeline Sys. Review
Review of preclinical interventions for heat stroke pathophysiology and gaps Heat Stroke Harms Your Cells: New Clues Could Change Treatment
This narrative review synthesizes preclinical evidence on several compounds for heat stroke pathophysiology. The authors note mitochondrial …
Heat stroke doesn't just raise your temperature, it shuts down your cells' power plants, and new research points to ways of protecting them …
Frontiers May 13, 2026
Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients
Dermatology Meta-analysis
Meta-analysis of sirolimus for cutaneous squamous cell carcinoma in kidney transplant recipients Sirolimus lowers skin cancer risk in kidney transplant patients
This meta-analysis of four randomized trials in kidney transplant recipients with prior cutaneous squamous cell carcinoma found that switchi…
A review of studies shows switching to sirolimus can cut skin cancer rates, but it may cause more side effects.
May 2, 2026
Paclitaxel-coated balloons and sirolimus-eluting stents in noncomplex coronary bifurcation lesions
Cardiology RCT
Paclitaxel-coated balloons and sirolimus-eluting stents in noncomplex coronary bifurcation lesions Drug coated balloons show similar results for certain artery blockages
This randomized noninferiority trial subgroup analysis evaluated 2,257 participants with de novo coronary lesions.
New data suggests drug coated balloons may work as well as traditional stents for specific types of coronary artery blockages.
Apr 30, 2026
Sirolimus-eluting iron bioresorbable scaffold shows higher late lumen loss than everolimus-eluting stents in coronary artery disease patients
Cardiology RCT
Sirolimus-eluting iron bioresorbable scaffold shows higher late lumen loss than everolimus-eluting stents in coronary artery disease patients New iron scaffold matches metal stents for heart artery repair
This randomized trial enrolled 518 patients with myocardial ischemia and 1 or 2 de novo target lesions at 36 centers in China.
A new iron heart scaffold matches metal stents in safety and effectiveness while dissolving over time.
Apr 29, 2026
Computational model review predicts dual optima for combination therapy in ageing
Drug Pipeline
Computational model review predicts dual optima for combination therapy in ageing New math model shows combining drugs could slow aging better than weight loss alone
This review of a computational model explores combination therapy with semaglutide, SGLT2 inhibitors, metformin, and rapamycin for ageing.
A new computer model reveals that fixing blood sugar and slowing aging are separate tasks, meaning some drugs might help you live longer eve…
medRxiv Apr 24, 2026
High NSUN3 expression linked to poor survival in oral squamous cell carcinoma
Oncology Cohort
High NSUN3 expression linked to poor survival in oral squamous cell carcinoma High NSUN3 protein makes oral cancer spread faster
This cohort study of 60 oral squamous cell carcinoma patients found that upregulated NSUN3 expression is an independent risk factor for poor…
Imagine waking up with a sore in your mouth that won't heal.
Frontiers Apr 22, 2026
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Ophthalmology
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
medRxiv Apr 14, 2026
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation
Oncology Phase II
Itacitinib plus standard therapy in acute leukemia or myelofibrosis patients undergoing reduced-intensity conditioning donor stem cell transplantation Early trial explores itacitinib for stem cell transplant patients with blood disorders
This Phase IIa trial evaluated itacitinib combined with tacrolimus and sirolimus in patients with acute leukemia, myelodysplastic syndrome, …
A new trial adds itacitinib to standard care for stem cell transplant patients with blood disorders to help prevent graft-versus-host diseas…
CT.gov Apr 13, 2026
Rapamycin therapy reduced infections and lymph node size in a female child with APDS1
Rheumatology Sys. Review
Rapamycin therapy reduced infections and lymph node size in a female child with APDS1 Neck Mass Was Not Cancer, It Was This Rare Condition
This case report describes a single female patient with Activated phosphoinositide 3-kinase delta syndrome type I (APDS1) who received rapam…
A rare genetic immune disorder caused a neck mass mistaken for cancer, ending years of failed treatments for recurrent lung infections and s…
Frontiers Apr 11, 2026

All sirolimus Articles